ÂÜÀòÂÒÂ×

Clinton Musil joined Catalyst Biosciences as Chief Financial Officer in July 2020. Prior to joining Catalyst, he held the position of Chief Business Officer at Personalis, where he helped build a pipeline and rapidly scale revenue as well as complete the Company’s $150 million initial public listing. Prior to Personalis, Mr. Musil was a member of the executive management team at ARMO Biosciences, where he oversaw the Company’s initial public offering and $1.6 billion sale to Eli Lilly. In addition to his operational experience, Clinton brings an extensive background in healthcare investment banking. Earlier in his career, Mr. Musil served in various positions at Gilead Sciences and Sanofi.

Mr. Musil received a B.S. in Molecular and Cellular Biology from the University of Arizona and an M.B.A. from Harvard Business School.